Clinical trials
Mild Cognitive Impairment Due to Alzheimer's Disease clinical trials
Below are recruiting mild cognitive impairment due to alzheimer's disease clinical trials, each written for real people, not researchers. We’re tracking 103 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02811653Recruiting
Brain movement and memory study in early dementia
This study looks at how “slower movement” and brain changes relate to memory and thinking problems in people with early dementia (and some related conditions). It may help researchers understand what brain differences go with these symptoms, using tests and an MRI scan.
AmiensAges 40–85 - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Birmingham, AlabamaAges 50–90 - NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Phoenix, ArizonaAges 50–85 - NCT07214727RecruitingPhase 1
A study of ALN-5288 for Alzheimer's disease
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
MontrealAges 40–80 - NCT07497334Recruiting
Combined therapy for older adults with mild thinking and mobility issues
This study tests a program that combines mental exercises, physical training, and brain stimulation to help older adults with mild thinking and mobility problems stay independent. It aims to improve walking, memory, and daily function.
Hong KongAges 60–90 - NCT07234942RecruitingPhase 1
Safety study of RO7812653 for early Alzheimer's disease
This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.
Toronto, OntarioAges 50–75 - NCT07224607Recruiting
Light therapy for early Alzheimer's disease
This study tests a type of light therapy (called transcranial photobiomodulation) to see if it can help people with early-stage Alzheimer's. It involves coming to Cedars-Sinai for weekly sessions over a period of time.
Los Angeles, CaliforniaAges 55–89 - NCT05456503RecruitingPhase 3
PET scan study of tau buildup in memory and brain disorders
This Phase 3 study uses a PET/CT scan to measure whether a brain protein called tau (and related disease patterns) builds up in different dementia conditions. The goal is to better match which disorders have which brain changes and how they progress.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07392723RecruitingPhase 2
Flaxseed nutrition to protect memory in APOE4 adults
This study tests a special flaxseed-based nutrition drink to see if it can slow memory loss in older adults who have the APOE4 gene and mild cognitive impairment (early memory trouble). If you qualify, you'll take the drink daily for a year and have memory tests and brain scans.
New Brunswick, New JerseyAges 60 years+ - NCT07252440RecruitingPhase 2
Testing an oral drug for early Alzheimer's disease
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
Chongqing, Chongqing MunicipalityAges 55–85 - NCT05405075Recruiting
Alzheimer’s research study with brain tests and blood samples
This study supports Alzheimer’s research by collecting health and thinking (cognitive) test results and blood samples to study genetics and biomarkers. You may be enrolled if you’re age 40 or older and can do these checkups, even if you have mild memory problems or dementia.
Phoenix, ArizonaAges 40 years+ - NCT07109999Recruiting
Biomarker study for Alzheimer's disease
This study uses brain scans or spinal fluid tests to confirm Alzheimer's-related changes. It aims to track the disease over time to better understand and improve care.
Beijing, Beijing MunicipalityAges 40 years+ - NCT03035851Recruiting
Exercise program for older adults at risk of memory decline
This trial tests whether a structured aerobic (heart-pumping) exercise program can improve memory and thinking in older adults who feel memory trouble but have not been diagnosed with dementia. It focuses on people who are “at increased risk” due to common health factors like high blood pressure or diabetes.
Calgary, AlbertaAges 50–80 - NCT06375213Recruiting
Memory and thinking study for all ages
This study looks at how well people think and remember as they age. It includes healthy volunteers, people with mild memory issues, and those with dementia—both early- and late-onset.
Pathum Wan, BangkokAges 35 years+ - NCT06775964RecruitingPhase 1/Phase 2
Stem cell therapy for early Alzheimer's disease
This trial tests a stem cell treatment for people with early-stage Alzheimer's disease. It aims to see if the treatment can help slow memory loss or other symptoms. You must have a specific blood test showing inflammation in the body to qualify.
Houston, TexasAges 60–80 - NCT06094192Recruiting
Brain stimulation to improve memory in Alzheimer's
This study tests whether a gentle, noninvasive brain stimulation technique called tACS can help improve memory in people with Alzheimer's disease or mild cognitive impairment. It may also include healthy older adults for comparison.
Boston, MassachusettsAges 50–100 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Irvine, CaliforniaAges 50–85 - NCT06923007Recruiting
Vagus nerve stimulation for Alzheimer's disease
This trial tests if a nerve stimulation device can help people with mild to moderate Alzheimer's. It is for patients aged 50 to 80 who are on a stable medication.
BeijingAges 50–80 - NCT06129838Recruiting
Inflammation in Alzheimer's disease using a brain scan
This study uses a special PET scan to look for inflammation in the brains of people with Alzheimer's or related dementias. It may help researchers understand how inflammation affects memory and thinking problems.
St Louis, MissouriAges 50 years+ - NCT06080659Recruiting
Brain network study for Alzheimer's and Parkinson's
This study uses brain scans to look for patterns that might help diagnose memory or movement problems like Alzheimer's or Parkinson's disease. It compares people with mild symptoms, like forgetfulness or early Parkinson's, to healthy volunteers.
RennesAges 50–80 - NCT05326750Recruiting
Brain stimulation to help diagnose and manage memory conditions
This trial studies a non-invasive brain-stimulation approach to help doctors assess and manage certain brain-related conditions. You might benefit by contributing to better diagnostic tools and treatment planning for memory and thinking problems.
KuopioAges 18 years+ - NCT07688460RecruitingPhase 4
Blood test to monitor Alzheimer's drug Lecanemab
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
Yiwu, ZhejiangAges 50–90 - NCT06801639Recruiting
Brain stimulation at home for mood symptoms in Alzheimer's
This study tests if a gentle brain stimulation technique, called tDCS, can help improve mood symptoms like depression, anxiety, or irritability in people with Alzheimer's or mild cognitive impairment. A caregiver will help with the sessions at home, and all visits are done remotely.
San Antonio, TexasAges 60–85
Hear when a new Mild Cognitive Impairment Due to Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mild cognitive impairment due to alzheimer's disease?
- Yes. Clin2 currently lists 103 recruiting mild cognitive impairment due to alzheimer's disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mild cognitive impairment due to alzheimer's disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mild cognitive impairment due to alzheimer's disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.